Chronic graft-versus-host disease in the era of post-transplant cyclophosphamide
Chronic graft-versus-host disease (cGVHD) remains a leading cause of late morbidity after allogeneic hematopoietic cell transplantation (HCT), but its phenotype under modern prophylaxis with post-transplant cyclophosphamide (PTCy) is not well characterized. We conducted a prospective, single-center study of 600 consecutive adults undergoing HCT with PTCy-based prophylaxis to assess incidence, clinical manifestations, treatment response, prognostic factors, and outcomes. Donors included matched siblings (36%), matched unrelated (34%), haploidentical (24%), and mismatched unrelated (6%). The 1-year cumulative incidence of moderate-to-severe cGVHD was 22% (95% CI, 19-26%). The mouth was the most frequently involved organ (64%), with lichen planus-like changes as the predominant diagnostic feature, whereas sclerotic forms were uncommon. Notably, 27% of moderate-to-severe cases were managed successfully without systemic corticosteroids. The cumulative incidence of systemic therapy requirement was 15% at 1 year, with risk significantly higher in donors ≥30 years and in female-to-male transplants. Among 105 patients requiring systemic steroids, 64% achieved complete response, 32% discontinued immunosuppression, yet 18% developed cGVHD-related sequelae. Mouth ulcers and erythema, as well as a lung score ≥2 at steroid initiation independently predicted shorter failure-free survival. At 2 years, overall survival, cGVHD-free relapse-free survival, and GVHD-free relapse-free survival were 76% (95% CI, 72-79), 63% (95% CI, 60-68), and 57% (95% CI, 53-62), respectively. In conclusion, after HCT with PTCy-based prophylaxis, systemic therapy was required in only a minority of patients, with risk influenced by donor age and sex mismatch rather than donor type. While corticosteroids were generally effective, a substantial subset required salvage therapy, underscoring the burden of refractory cGVHD and the need for steroid-sparing approaches and novel interventions.
Authors
- Brais Lamas
- Marta Villalba (ORCID: https://orcid.org/0000-0003-3094-331X)
- Marta Isabel González de la Rubia
- A. Hervás
- Juan Pablo Reig
- Ana Bataller (ORCID: https://orcid.org/0009-0000-0378-550X)
- Marta García Gamón Valero
- Pablo Granados
- CARLA SATORRES
- Miguel Mansilla-Polo
- Gómez-Seguí Inés
- Juan Montoro
- Miguel A. Sanz
- Lara Eritzpokhoff
- Nalle Vallejo
- Guillermo León
- Mercedes Hurtado
- Alberto Louro
- Javier López
- Juan Eirís
- Javier De la Rubia
- Pedro Chorão
- Pedro Asensi Cantò
- Pilar Solves
Institutions
- Mexican Social Security Institute (MX)
- Hospital Universitari i Politècnic La Fe (ES)
- Fundación Universitaria Sanitas (CO)
- Instituto de Investigación Sanitaria La Fe (ES)
Publication Details
- Journal
- Haematologica
- Published
- 2026-01-22
- DOI
- https://doi.org/10.3324/haematol.2025.289266
- Citations
- 1
- Primary Topic
- Hematopoietic Stem Cell Transplantation
- Type
- article
- Field-Weighted Citation Impact
- 35.41
Funders
- Sanofi
- European Commission
- Instituto de Salud Carlos III